Head to Head Survey: Teligent (TLGT) vs. Pernix Therapeutics (PTX)
Teligent (NASDAQ: TLGT) and Pernix Therapeutics (NASDAQ:PTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.
Earnings & Valuation
This table compares Teligent and Pernix Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Teligent||$66.88 million||2.35||-$11.98 million||($0.23)||-12.78|
|Pernix Therapeutics||$140.86 million||0.19||-$169.59 million||($13.62)||-0.16|
Volatility and Risk
Teligent has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Comparatively, Pernix Therapeutics has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.
This is a summary of current recommendations and price targets for Teligent and Pernix Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Teligent currently has a consensus target price of $7.00, suggesting a potential upside of 138.10%. Given Teligent’s higher possible upside, research analysts clearly believe Teligent is more favorable than Pernix Therapeutics.
This table compares Teligent and Pernix Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
72.1% of Teligent shares are owned by institutional investors. Comparatively, 16.4% of Pernix Therapeutics shares are owned by institutional investors. 22.6% of Teligent shares are owned by company insiders. Comparatively, 1.4% of Pernix Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Teligent beats Pernix Therapeutics on 9 of the 13 factors compared between the two stocks.
Teligent, Inc. is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 34 Abbreviated New Drug Application(ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2016.
About Pernix Therapeutics
Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. Its products include Treximet, indicated for acute migraine; Zohydro ER with BeadTek, an extended-release opioid agonist indicated for the management of pain severe; Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla for major depressive disorder. It promotes selected non-core branded products, such as its cough and cold products, through co-promotion arrangements with third-party sales organizations, and distributes its generic products through its subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc.
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.